strong organ growth corpor brokerag ep beat
arthur gallagh result per share best forecast
consensu due larg less expect loss corpor segment
brokerag earn penni higher expect organ growth
better expect margin modestli higher expect well risk
manag ep match forecast manag complet acquisit
million annual revenu quarter forecast anoth
million januari aid top line go forward
commission/fe organ growth brokerag segment beat
forecast organ growth volatil howev base current trend
manag commentari regard market condit ajg initi
increas confid forecast look organ growth
modestli previou forecast improv forward outlook
somewhat conserv assum organ growth sustain go
forward assum compani continu activ acquir
increas earn estim
project note given recent trend increas
organ growth assumpt addit increas project acquir
revenu continu model modest ebitdac margin improv
po base cash ep modest premium
compar compani see justifi given ajg better-than-expect
growth opportun driven success on-going strategi averag
organ growth oper leverag allow on-going margin improv
lead double-digit ep growth next sever year
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price
object basis/risk page
total benefit claim
total invest
oper return averag asset
long term debt cap ratio ex fa
amtz dac pre-tax profit bef amtz dac
arthur gallagh world fourth-largest
risk manag servic via network
subsidiari place p/c reinsur surplu
line manag employe benefit program
risk manag servic perform
manag loss control consult worker
believ one best-run middle-
market insur broker organ growth
respond better price econom
environ growth along good
expens disciplin allow continu
margin improv acquisit remain
attract avenu growth above-averag
dividend yield attract sustain
invest incom
gain book sale
chang acquisit earn out/oth
earn incom tax es
provis incom tax es
earn incom tax es
provis incom tax es
organ growth fee
bofa merril lynch global research compani document
estimate
earn incom tax
provis incom tax
invest incom
chang acquisit earn out/oth
earn incom tax
provis incom tax
bofa merril lynch global research compani document
invest incom
chang acquisit earn out/oth
earn incom tax
provis incom tax
compani document bofa merril lynch global research
tabl arthur gallagh risk manag corpor mn
earn incom tax
provis incom tax
organ growth fee
earn incom tax
provis incom tax
compani document bofa merril lynch global research
invest incom
chang acquisit earn out/oth
earn incom tax
provis incom tax
bofa merril lynch global research compani document
po base cash ep modest premium
compar compani see justifi given better-than-expect
growth opportun driven success on-going strategi averag
organ growth oper leverag allow on-going margin improv
lead double-digit ep growth next sever year downsid risk
price object softer property-casualty price built
expect poor integr one sever acquisit lower industry-wid claim
frequenc hurt claim manag busi rise unemploy
could hurt claim manag busi expos worker
compens residu environment tax liabil relat synthet coal
invest chang health care regul impact benefit broke
busi chang dividend strategi compani
alison jacobowitz herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
